β-干扰素治疗的多发性硬化症患者中的抗细胞因子抗体及检测需求：神经科医生面临的困境 - Suppr

Suppr

超能文献

Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist.

作者信息

Pachner A R

机构信息

Department of Neurology, Georgetown University Medical Center, Washington, DC, USA.

出版信息

Neurology. 1997 Sep;49(3):647-50. doi: 10.1212/wnl.49.3.647.

DOI:10.1212/wnl.49.3.647

PMID:9305316

Abstract

摘要

相似文献

Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist.β-干扰素治疗的多发性硬化症患者中的抗细胞因子抗体及检测需求：神经科医生面临的困境

Neurology. 1997 Sep;49(3):647-50. doi: 10.1212/wnl.49.3.647.

Measurement of antibodies to interferon beta in patients with multiple sclerosis.多发性硬化症患者中抗β干扰素抗体的检测

Arch Neurol. 2001 Aug;58(8):1299-300. doi: 10.1001/archneur.58.8.1299.

Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.中和抗体与干扰素β-1b在复发缓解型多发性硬化症中的疗效

Mult Scler. 1997 Dec;3(6):402. doi: 10.1177/135245859700300610.

Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis.在多发性硬化症的β-干扰素-1b（IFN-β-1b）治疗期间中和及结合抗β-干扰素-1b（IFN-β-1b）抗体

Mult Scler. 1997 Jun;3(3):184-90. doi: 10.1177/135245859700300303.

The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.干扰素β治疗的多发性硬化症患者中中和抗体的意义。

Arch Neurol. 2001 Aug;58(8):1297-8. doi: 10.1001/archneur.58.8.1297.

[Formation of neutralizing antibodies in therapy of multiple sclerosis with interferon beta-1b. Practical procedure in suspected therapeutic failure].[用β-1b干扰素治疗多发性硬化症时中和抗体的形成。疑似治疗失败的实际处理方法]

Nervenarzt. 1997 Dec;68(12):935-9. doi: 10.1007/s001150050219.

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b.接受β-1b干扰素治疗的多发性硬化症患者体内中和抗体的演变

Neurology. 1999 Apr 12;52(6):1277-9. doi: 10.1212/wnl.52.6.1277.

Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis.多发性硬化症患者针对干扰素β的抗体反应的定性和定量分析。

Mult Scler. 2006 Dec;12(6):738-46. doi: 10.1177/1352458506070968.

Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.中和抗体（NABS）与多发性硬化症的干扰素β-1b治疗

Funct Neurol. 2001 Apr-Jun;16(2):117-28.

Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS.血液白细胞中的Mx蛋白用于监测多发性硬化症患者的干扰素β-1b治疗。

Neurology. 2000 Jan 11;54(1):193-9. doi: 10.1212/wnl.54.1.193.

引用本文的文献

Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients.血清脂质谱变化可预测干扰素β-1a治疗的多发性硬化症患者的神经退行性变。

J Lipid Res. 2017 Feb;58(2):403-411. doi: 10.1194/jlr.M072751. Epub 2016 Dec 6.

The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study.中和抗体对干扰素 β 治疗的复发型多发性硬化症疾病恶化风险的影响：一项上市后 5 年研究。

J Neurol. 2013 Jun;260(6):1562-8. doi: 10.1007/s00415-012-6829-3. Epub 2013 Feb 17.

MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity.MxA基因表达分析作为多发性硬化症患者干扰素-β生物活性的测量方法以及抗体介导的生物活性降低的鉴定

Mol Diagn. 2003;7(1):17-25. doi: 10.1007/BF03260016.

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.三种β干扰素对多发性硬化症患者中和抗体的不同影响：在独立实验室进行的一项随访研究

J Neurol Neurosurg Psychiatry. 2002 Aug;73(2):148-53. doi: 10.1136/jnnp.73.2.148.

Interferon in relapsing-remitting multiple sclerosis.干扰素在复发缓解型多发性硬化症中的应用

Cochrane Database Syst Rev. 2001;2001(4):CD002002. doi: 10.1002/14651858.CD002002.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验